Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab versus ustekinumab in moderate to severe plaque psoriasis
NL-OMON42355Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing Ixekizumab arm with Ustekinumab arm (2 arms). Primary endpoint: PASI 90 at Week 12. Started Oct 2015; status: active, not recruiting.
02
Drugs
ixekizumabustekinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NL-OMON42355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42355.